CQDM/CIHR Collaborative Funding Program in Personalized Medicine to Accelerate Drug Discovery
CQDM and CIHR, with five of its institutes, partner in a new
collaborative funding program in personalized medicine across Canada,
to accelerate drug discovery and drug development. This new initiative was launched at the event BioTransfer2014.
Please click here for the call for proposals. Complementary to former initiatives in personalized medicine, this new national program offers public and private partners the opportunity to work together to develop new cutting-edge technologies, computational tools and devices which will in turn accelerate R&D in the area of personalized medicine. To be eligible, research must be performed in Canada with at least one researcher based at a university or affiliated research institution or hospital and at least one researcher at a small and medium-sized enterprise (SME) or not-for-profit organization with important research activities.
The deadline to submit a letter of intent is June 27, 2014. For more information, please visit CQDM’s Web site for program detaills.
Personalized medicine is developing at a rapid pace which brings new challenges as well as opportunities to the whole spectrum of therapeutic development, from basic research to its integration in the drug discovery process. In an effort to bring solutions which will address the most urgent needs of biopharmaceutical research, CQDM and CIHR will fund research projects focused on the invention and development of next-generation of technologies, computational tools and devices in the following research areas:
- infection and immunity;
- neurodegeneration affecting cognition.